Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma

Inclusion Criteria: * signed informed consent * patients 18 years of age or older * biopsy proven, non-recurrent primary adenocarcinoma of the thoracic esophagus or gastro-esophageal junction, disease confined to esophagus and peri-esophageal soft tissue, tumors at the gastroesophageal junction must be limited to no greater than 2 cm into the gastric cardia * clinical stage T3, N0-1 or T1-2, N1 and M0 or M1a (celiac axis lymph nodes are allowed) * Karnofsky Performance Status of \>60% * forced expiratory volume at one second (FeV1) must be \>1.0 L * adequate bone marrow reserve equal to or absolute neutrophil count (ANC) \> 1500/mcl, total white blood cell count (WBC) \> 3000/mcl, platelets \>100,000/mcl and hemoglobin \> 10.0 g/dl (transfusion permitted) * adequate hepatic function of direct serum bilirubin \< 2 times the upper limit of normal, total bilirubin \< 1.5 times the upper limit normal, alanine transaminase (ALT), aspartate transaminase (AST) \< 2.5 times the upper limit normal, Alkaline phosphatase \< 2.5 times the upper limit normal * creatinine clearance \> 50 ml/min * female patients of childbearing potential must have a negative serum or urin pregnancy test within 7 days prior to starting therapy Exclusion Criteria: * no previous resection or attempted resection of an esophageal cancer * women who are pregnant or lactating * life expectancy \< 3 months * serious, uncontrolled concurrent infection(s) * prior fluoropyrimidine therapy * prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil or known Dihydro Pyrimidine Dehydrogenase Deficiency (DPD) deficiency * treatment for other carcinomas within 5 years, except cured non-melanoma skin and treated in-situ cervical cancer * history of or evidence of uncontrolled diabetes * surgical procedure within 6 months of study entry * participation in any investigational drug study within 4 weeks preceding the start of study treatment * prior therapy with andy agent that specifically targets the Epidermal Growth Factor Receptor (EGFR) pathway * prior severe infusion reaction to a monoclonal antibody * acute hepatitis or known HIV * clinically significant cardia disease * evidence of metastases * other serious uncontrolled medical conditions that the investigator feels might compromise study participation * major surgery within 4 weeks of the start of treatment without complete recovery * lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome * known, existing uncontrolled coagulopathy * unwillingness to give written informed consent * unwillingness to participate or inability to comply with the protocol for the duration of the study * neuropathy of grade 2 or greater